Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to suppo ...
NEWTOWN SQUARE, Pennsylvania – ArriVent BioPharma, Inc. (NASDAQ:AVBP) hat mit der Behandlung des ersten Patienten in seiner globalen, zulassungsrelevanten Phase-3-Studie ALPACCA begonnen. Dies gab das ...
Investing.com – Cantor Fitzgerald hat am Montag die Bewertung von ArriVent BioPharma (NASDAQ:AVBP) mit der Einstufung ...
KUALA LUMPUR, MY / ACCESS Newswire / December 23, 2025 / This festive season, Hektar Malls invites families to step into a world of creativity, imagination and togetherness with "Elf Builders ...
Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies([1]) , with the FDA fast-tracking multiple targeted therapies designed to ...
Investing.com - Cantor Fitzgerald initiated coverage of ArriVent BioPharma (NASDAQ:AVBP) with an Overweight rating on Monday. The clinical-stage biopharmaceutical company, currently trading at $22.40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback